Vimarsana
Biggest News Aggregation in the World

Page 2 - Evaj Pell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Evaj Pell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Evaj Pell Today - Breaking & Trending Today

Study to explore potential for monkeypox virus to spread to livestock - Vimarsana News

Study to explore potential for monkeypox virus to spread to livestock

First step toward understanding monkeypox's ability to replicate in the respiratory cells of cattle and pigs in a controlled in vitro environment.

What are potential animal reservoirs for monkeypox? | Penn State University - Vimarsana News

What are potential animal reservoirs for monkeypox? | Penn State University

Penn State researchers will study the monkeypox virus to understand the potential for it to spill over from humans to animals, as well as its pathogenesis — or disease development — in animal and human cells in vitro. In addition, they will study potential targets for therapeutics to treat the monkeypox disease.

Source: psu.edu
Just for Kids at BookFest May 1 - Vimarsana News

Just for Kids at BookFest May 1

This year’s Children’s Corner at the Literary Hill BookFest promises to be the best yet! Capitol Hill schoolteacher Nicole Siegel is coordinating a day of activities guaranteed to delight youngst

Penn State University: Repurposing FDA-approved drugs may help combat COVID-19 - Vimarsana News

Penn State University: Repurposing FDA-approved drugs may help combat COVID-19

Several FDA-approved drugs — including for type 2 diabetes, hepatitis C and HIV — significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically

Repurposing FDA-approved drugs may help combat COVID-19 - Vimarsana News

Repurposing FDA-approved drugs may help combat COVID-19

Several FDA-approved drugs — including for type 2 diabetes, hepatitis C and HIV — significantly reduce the ability of the Delta variant of SARS-CoV-2 to